Central Centrifugal Cicatricial Alopecia (CCCA): Complete Guide

What Is CCCA?

Central centrifugal cicatricial alopecia (CCCA) is a primary scarring (cicatricial) alopecia that originates at the vertex (crown) of the scalp and spreads centrifugally — outward in all directions from that central point. As it advances, it permanently destroys hair follicles and replaces them with fibrous scar tissue. It is the most common primary scarring alopecia in women of African descent and represents a significant, underrecognized cause of permanent hair loss in this population.

The name encodes the condition's defining features:

• Central — it begins at the crown, not the hairline
• Centrifugal — spreads outward from that origin
• Cicatricial — scar-forming, meaning follicular destruction is irreversible
• Alopecia — hair loss

CCCA was previously conflated with other conditions under various names (hot-comb alopecia, follicular degeneration syndrome), but it is now recognized as a distinct entity with both genetic and environmental drivers.

Who Gets CCCA?

CCCA occurs almost exclusively in women of African descent. Prevalence estimates from published studies range from 2.7% to 5.6% of Black women in the general population, with one community-based study of 326 African American women reporting prevalence as high as 28% — a figure reflecting the high but often unrecognized burden of this condition.

CCCA is not exclusively a disease of adulthood. It can appear in adolescents, and its presence in teenage girls — documented in several published case series — underscores the importance of early screening in at-risk young women. Men of African descent can be affected but far less commonly.

Important: CCCA occurs in women who have never used chemical relaxers and in women who have never worn high-tension hairstyles. While styling practices appear to modulate the severity and onset, they are not the sole cause.

Causes and Pathogenesis

CCCA is a multifactorial condition. Current evidence implicates both genetic susceptibility and environmental triggers.

Genetic Factors

Mutations in the PADI3 gene (which encodes peptidylarginine deiminase 3 — an enzyme that post-translationally modifies proteins essential for hair shaft formation) have been identified in some CCCA cases. This gene variant can be inherited in an autosomal dominant pattern with partial penetrance. When a PADI3 mutation is present, the inner root sheath — the structural scaffold that surrounds the growing hair shaft — is abnormal, making the follicle more vulnerable to mechanical stress and inflammatory destruction.

A family history of central scalp hair loss in female relatives should raise clinical suspicion for CCCA.

Hair Care Practices

Certain hair care practices have been epidemiologically associated with CCCA risk or severity, though causation is complex:

• Thermal straightening: hot combs and flat irons applied directly to the scalp, not just the hair shaft, can cause repeated heat injury to the follicular infundibulum
• Chemical relaxers: disruption of the hair shaft's disulfide bonds weakens the interface between the inner root sheath and the hair shaft
• High-tension hairstyles: braids and extensions applied to the vertex specifically may compound follicular mechanical stress

However, as noted, none of these practices are necessary for CCCA to develop — they appear to exacerbate disease in genetically susceptible individuals.

Pathophysiology

The current leading hypothesis is that the primary event is immune-mediated follicular destruction — a targeted inflammatory attack on the isthmus and infundibulum of the follicle. This produces lymphocytic perifolliculitis (predominantly CD4+ T-cell infiltrate) that, over time, induces fibrosis around and eventually within the follicle. The sebaceous gland is characteristically absent in affected areas.

More recent work notes that in late-stage CCCA, active inflammation is often absent histologically, replaced by concentric lamellar fibrosis — suggesting a separate fibroproliferative mechanism may perpetuate the condition beyond its inflammatory phase. A 2019 PMC study confirmed preferential expression of fibroproliferative genes in CCCA scalp biopsies.

Comorbidities

Several studies have examined metabolic associations:

• Type 2 diabetes: associated with CCCA in three of five published studies reviewed in a 2023 PMC systematic analysis; the association was significant in a 326-patient study but not replicated in a larger 2,482-patient multicenter database
• Uterine leiomyomas (fibroids): consistently associated with CCCA across multiple studies — the fibroproliferative biology of CCCA may share pathways with fibroid development
• Hyperlipidemia and vitamin D deficiency: also reported associations

Given these findings, metabolic screening is a reasonable clinical consideration at the time of CCCA diagnosis.

Signs and Symptoms

CCCA progresses insidiously. Many women notice hair thinning at the crown years before seeking evaluation, having attributed it to normal aging, heat damage, or stress.

Scalp Symptoms (Active Inflammatory Phase)

• Scalp tenderness or soreness at the crown — often described as a burning or itching sensation
• Scaling and flaking at the vertex, sometimes confused with seborrheic dermatitis
• Pustules or folliculitis at the crown (less common than in traction alopecia)
• The scalp may feel chronically sensitive to touch or heat

Hair Loss Pattern

• Vertex-central onset: begins at the very top of the crown
• Centrifugal spread: advances outward symmetrically in all directions; the most recently affected zone (the active leading edge) surrounds a central bald patch
• The frontal hairline is typically preserved until very advanced disease, distinguishing CCCA from female pattern hair loss and frontal fibrosing alopecia
• Hair density at the leading edge may show follicular units with reduced shaft number (polytrichia replaced by single hairs)

Advanced Disease

In areas of established scarring, the scalp surface is smooth, atrophic, and shiny. Follicular openings are absent or reduced on dermoscopy. The patch is non-inflamed and feels firm on palpation.

Diagnosis

Clinical Examination + History

A dermatologist diagnosing CCCA will assess:

• Pattern and duration of hair loss (vertex-centered with centrifugal spread)
• Family history of central scalp hair loss in female relatives
• Hair care practice history (relaxers, thermal tools, high-tension styles)
• Scalp symptoms (tenderness, burning, itch)

Dermoscopy

Dermoscopy (trichoscopy) findings in CCCA include:

• Peripilar gray-white halos — a ring of gray or white discoloration around follicles at the active edge; considered a hallmark finding in skin of color
• Reduced follicular density at the vertex with single terminal hairs replacing polytrichia
• In active disease: perifollicular scaling and erythema
• In late disease: complete loss of follicular openings over the scarred area

Scalp Biopsy

A 4 mm punch biopsy from the active margin (not the central scar) is the gold standard for confirmation. Histology shows:

• Concentric lamellar fibrosis around the isthmus
• Perifollicular lymphocytic inflammation (CD4+ T-cells)
• Loss of the sebaceous gland
• In late disease: severe fibrosis with few remaining follicles and absent inflammation

Biopsy is particularly important to distinguish CCCA from alopecia areata, discoid lupus erythematosus (DLE), and lichen planopilaris — all of which can affect the vertex and require different treatments.

Differential Diagnosis

Treatment

No treatment can reverse scarring already established. The goal of all current therapies is to arrest inflammation before it destroys more follicles. The earlier treatment begins, the more of the original follicular reservoir is preserved.

First-Line: Intralesional Corticosteroids

Intralesional triamcinolone acetonide (ILT) is the cornerstone first-line treatment:

• Injected at the active inflammatory margin (not the central scar) by a dermatologist
• Standard concentration: 2.5–10 mg/mL
• Interval: every 4–8 weeks
• Reduces perifollicular inflammation acutely and can slow centrifugal expansion

First-Line: Oral Doxycycline

Doxycycline 100 mg twice daily for up to six months is recommended by the AAD and confirmed by a Delphi consensus of 21 nationwide US hair specialists. Doxycycline is used not primarily as an antibiotic but for its anti-inflammatory properties — it inhibits matrix metalloproteinases and suppresses inflammatory cytokine cascades involved in follicular destruction.

Second-Line: Hydroxychloroquine

Hydroxychloroquine 200–400 mg/day is used when patients do not adequately respond to ILT and doxycycline. It is an antimalarial drug with established anti-inflammatory and immunomodulatory properties used in lichen planopilaris and other lymphocytic alopecias. Regular ophthalmological monitoring is required during use.

Adjunctive: Minoxidil

Topical minoxidil 2–5% and low-dose oral minoxidil (0.25–1.25 mg/day for women, or up to 2.5 mg/day per clinician discretion) are used alongside anti-inflammatory treatment to:

• Prolong the anagen phase in still-viable follicles at the active margin
• Improve density in the transitional zone between active disease and established scarring
• Note: minoxidil cannot restore hair to areas already replaced by scar tissue

A 2024 PMC case report documented hair regrowth in a patient with CCCA treated with the JAK inhibitor baricitinib, and topical ruxolitinib combined with oral minoxidil has also been reported — these represent emerging options for refractory disease, not yet standard of care.

Lifestyle and Hair Care Modifications

Per AAD recommendations:

• Discontinue or minimize chemical relaxers
• Avoid applying direct heat to the scalp
• Limit high-tension hairstyles, particularly at the crown
• Use anti-dandruff or medicated shampoos (ketoconazole, zinc pyrithione) if seborrheic dermatitis co-exists, as yeast overgrowth may compound inflammation
• Wash hair frequently to remove scalp build-up; less frequent washing of natural textured hair has been associated with higher sebum and product accumulation on the scalp

Emerging Treatments

JAK inhibitors (upadacitinib, ruxolitinib, baricitinib) are under active investigation for refractory CCCA based on the T-cell inflammatory mechanism. Published case reports and one 2024 PMC case series show promising regrowth signals, but these remain experimental options for specialist centers. LED light therapy (Revian Red cap) is also under investigation in registered clinical trials.

Hair Transplantation

Transplantation can restore hair to areas of stable, long-standing scarring once disease has been inactive (no active inflammation, no expansion) for at least one to two years. Because CCCA is a progressive disease that can reactivate, ongoing anti-inflammatory maintenance therapy is typically continued post-transplantation.

Monitoring and Prognosis

CCCA requires long-term dermatological follow-up. Even when inflammation is controlled, the disease can reactivate. Serial photography, dermoscopy, and patient-reported symptom tracking are standard. Response to treatment is assessed at three to six months.

With early treatment, most women can maintain their current hair density and prevent further expansion. Without treatment, CCCA progresses inexorably — the rate of expansion varies widely between individuals but does not spontaneously remit.

For related hair conditions, see the Hair Loss & Thinning hub or traction alopecia guide if you also wear high-tension hairstyles.